G6PD Deficiency in Infarction Patients in Shaanxi Province

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cerebral infarction brings heavy burden to patients and families with high morbidity, mortality, disability and recurrence rate. Anti-platelet aggregation therapy plays important role for secondary prevention of cerebral infarction. G6PD deficiency is a rare genetic disorder, patients with this disorder could suffer hemolysis after eating broad beans. Professor Zeng Jinsheng et al found that the hemolysis risk of G6PD deficiency patients was significantly increased when aspirin was applied in Guangdong Province. However, the prevalence of G6PD deficiency in northern China remains unknown, as well as the safety of antiplatelet therapy. To this end, 1000 patients with acute cerebral infarction will be continuously included in 30 second-level and above hospitals in 10 prefectures and cities of Shaanxi Province for observation and follow-up for 12 months, to explore the prevalence of G6PD deficiency in cerebral infarction patients in Shaanxi Province, and to analyze the relationship between G6PD deficiency and the clinical characteristics and prognosis of cerebral infarction. To clarify the efficacy and safety of antiplatelet therapy for G6PD patients with cerebral infarction is of great significance for guiding the individualized treatment of cerebral infarction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Variants in Stroke

NCT07186517

Stroke Genetic Association Studies

NOT_YET_RECRUITING

Genetic Identification of Monogenic Disorders in Early-onset Stroke Using Targeted Next Generation Sequencing Panel

NCT04485598

Stroke, Acute Transient Ischemic Attack Single-gene Disorders

COMPLETED

Genetic Variation in Platelet Aggregation

NCT01576536

Myocardial Infarction

COMPLETED

Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations

NCT00136630

Spinocerebellar Ataxias Spastic Paraplegias

COMPLETED

Longitudinal Study of Neurodegenerative Disorders

NCT03333200

MLD Krabbe Disease ALD +24 more

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Infarction G6PD Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

G6PD Deficiency

In the laboratory of the First Affiliated Hospital of Xi 'an Jiaotong University, tetrazolazole-blue quantitative method will be used to detect G6PD. According to the normal range of the tetrazole-blue quantitative method (6.8-20.5NBT), adults with G6PD activity \< 6.8NBT were positive, and G6PD deficiency is confirmed.

G6PD gene deficiency

Intervention Type GENETIC

we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.

Normal

The G6PD activity ranged from 6.8 to 20.5 NBT and the G6PD activity is normal.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

G6PD gene deficiency

we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* meets the diagnostic criteria of acute cerebral infarction established by Neurology Society of Chinese Medical Association, and confirmed by cranial Magnetic Resonance Imaging；
* Time from onset to enrollment ≤14 days;
* Volunteer to participate in the study and sign the informed consent.

Exclusion Criteria

* Silent cerebral infarction with no symptoms and signs;
* Complicated with post-infarction hemorrhage;
* Cerebral hernia and other complications caused by massive cerebral infarction may lead to death in acute phase;
* Cardiogenic cerebral embolism caused by atrial fibrillation;
* Cerebral infarction caused by tumor, vasculitis and other special reasons;
* Complicated with serious systemic diseases, including liver and kidney insufficiency, respiratory failure, heart failure, infection, etc

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No